Elisabet de los Pinos and her team fuel up for a late-stage quest to deliver a safe eye cancer drug
Since its founding in 2009, Aura Biosciences has been laser-focused on creating a safer alternative to currently available eye cancer therapies. And on Monday, the biotech pulled in $80 million to walk its lead candidate to Phase III.
The Series E round brings the Cambridge, MA-based company’s total raise to over $200 million. The biotech will use the funds for its virus-like drug conjugates, including its lead candidate, AU-011, which is headed for a pivotal late-stage study in choroidal (ocular) cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.